SANA vs. FUSN, INBX, CGON, HRMY, VCYT, BEAM, NVAX, DNA, KYMR, and NMRA
Should you be buying Sana Biotechnology stock or one of its competitors? The main competitors of Sana Biotechnology include Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), CG Oncology (CGON), Harmony Biosciences (HRMY), Veracyte (VCYT), Beam Therapeutics (BEAM), Novavax (NVAX), Ginkgo Bioworks (DNA), Kymera Therapeutics (KYMR), and Neumora Therapeutics (NMRA). These companies are all part of the "medical" sector.
Fusion Pharmaceuticals (NASDAQ:FUSN) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.
Sana Biotechnology has a net margin of 0.00% compared to Sana Biotechnology's net margin of -4,136.55%. Sana Biotechnology's return on equity of -48.74% beat Fusion Pharmaceuticals' return on equity.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Comparatively, 31.1% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Sana Biotechnology had 1 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 4 mentions for Sana Biotechnology and 3 mentions for Fusion Pharmaceuticals. Sana Biotechnology's average media sentiment score of 1.59 beat Fusion Pharmaceuticals' score of 1.39 indicating that Fusion Pharmaceuticals is being referred to more favorably in the media.
Fusion Pharmaceuticals received 29 more outperform votes than Sana Biotechnology when rated by MarketBeat users. Likewise, 64.06% of users gave Fusion Pharmaceuticals an outperform vote while only 50.00% of users gave Sana Biotechnology an outperform vote.
Fusion Pharmaceuticals presently has a consensus target price of $20.25, suggesting a potential downside of 5.59%. Sana Biotechnology has a consensus target price of $11.67, suggesting a potential upside of 49.57%. Given Fusion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Sana Biotechnology is more favorable than Fusion Pharmaceuticals.
Fusion Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.
Fusion Pharmaceuticals has a beta of -0.69, meaning that its share price is 169% less volatile than the S&P 500. Comparatively, Sana Biotechnology has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500.
Summary
Sana Biotechnology beats Fusion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Sana Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sana Biotechnology Competitors List
Related Companies and Tools
